David Suhy
Molecular and Cell Biology
Benitec Biopharma
Australia
Biography
David Suhy was appointed as our Chief Scientific Officer in April 2015, prior to which he served as our Senior Vice President, Research & Development since October 2012. In April 2008, he joined Tacere Therapeutics, Inc. as Director of Research & Development and continued in that role until our acquisition of Tacere in October 2012. Previous roles include Associate Director of R&D at Clontech Laboratories, Inc. and Principal Scientist at Antara Biosciences Inc. He also led the Target Validation Group at PPD Discovery, a company with proprietary technology surrounding the use of genetic suppressor elements to identify “druggable” genomic targets for large pharmaceutical companies. Dr Suhy holds a BS in Biochemistry and Biophysics from the University of Pittsburgh, earned his PhD in Biochemistry, Molecular Biology and Cell Biology at Northwestern University, and conducted his post-doctoral work at Stanford
Research Interest
Molecular and Cell Biology
